Plain-English translation of NCT06890065 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing JY231, an experimental therapy that uses your own immune cells to fight relapsed or refractory B-cell lymphomas and leukemias. The treatment works by collecting some of your blood cells, engineering them in a lab to recognize and attack cancer cells, and then infusing them back into your body. Researchers will follow you for up to 24 months to see if the treatment is safe and whether it helps control your cancer.
This medication is being studied because patients whose blood cancers have returned after initial treatment or stopped responding to chemotherapy have very limited options and poor prognoses. This new approach may offer hope by harnessing the power of a patient's own immune system to target cancer cells in a way that standard treatments cannot.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will first undergo a procedure called leukapheresis, where blood is drawn, some of your white blood cells are collected, and the blood is returned to you. You will then receive chemotherapy drugs (fludarabine and cyclophosphamide) for 3–5 days to prepare your body, followed by an intravenous infusion of the engineered cells. After that, you will have regular clinic visits and tests over 24 months so doctors can monitor your safety and check whether your cancer is responding to the treatment.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China